DK2626431T3 - Fremgangsmåde til diagnose, prognose og behandling af brystcancermetastase - Google Patents

Fremgangsmåde til diagnose, prognose og behandling af brystcancermetastase Download PDF

Info

Publication number
DK2626431T3
DK2626431T3 DK11791605.6T DK11791605T DK2626431T3 DK 2626431 T3 DK2626431 T3 DK 2626431T3 DK 11791605 T DK11791605 T DK 11791605T DK 2626431 T3 DK2626431 T3 DK 2626431T3
Authority
DK
Denmark
Prior art keywords
maf
breast cancer
metastasis
gene
bone
Prior art date
Application number
DK11791605.6T
Other languages
English (en)
Inventor
Cabré Roger Gomis
Sunyer María Tarragona
Estapé Anna Arnal
Milica Pavlovic
Original Assignee
Fundació Inst De Recerca Biomèdica Irb Barcelona
Fundació Privada Institució Catalana De Recerca I Estudis Avançats
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES201031478A external-priority patent/ES2379918B1/es
Application filed by Fundació Inst De Recerca Biomèdica Irb Barcelona, Fundació Privada Institució Catalana De Recerca I Estudis Avançats filed Critical Fundació Inst De Recerca Biomèdica Irb Barcelona
Application granted granted Critical
Publication of DK2626431T3 publication Critical patent/DK2626431T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast

Claims (13)

1. In vitro-fremgangsmåde til diagnosticering af knoglemetastase i et individ med brystcancer og/eller til prognose af tilbøjeligheden til at udvikle knoglemetastase i et individ med brystcancer, hvilken fremgangsmåde omfatter bestemmelse af, om c-MAF-genet er amplificeret i en tumorvævsprøve fra individet, hvor individet, hvis genet er amplifice-ret, har en positiv diagnose for metastase eller en større tilbøjelighed til at udvikle metastase.
2. Fremgangsmåde ifølge krav 1, hvor brystcanceren er ER+ eller ER-.
3. Fremgangsmåde ifølge krav 1 eller 2, hvor amplifikationen af c-MAF-genet bestemmes ved at bestemme amplifikationen af locusset 16q22-q24.
4. Fremgangsmåde ifølge krav 1 eller 2, hvor amplifikationen af c-MAF-genet bestemmes ved at anvende en c-MAF-genspecifik probe.
5. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 4, hvor kontrolprøven er en tumorvævsprøve af brystcancer fra et individ, som ikke har lidt af metastase.
6. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 5, hvor amplifikationen bestemmes ved in s/'ft/-hybridisering eller PCR.
7. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 6, hvor knoglemetastasen er osteolytisk metastase.
8. Anvendelse af et c-MAF-inhiberende middel til fremstilling af et medicinsk produkt til behandling og/eller forebyggelse af knoglemetastase ud fra brystcancer.
9. Anvendelse ifølge krav 8, hvor brystcanceren er ER+ eller ER-.
10.
Anvendelse ifølge krav 8 eller 9, hvor det c-MAF-inhiberende middel er valgt fra gruppen bestående af et c-MAF-specifikt siRNA, et c-MAF-specifikt antisense-oligo-nukleotid, et c-MAF-specifikt ribozym, et c-MAF-inhiberende antistof, en dominerende negativ c-MAF-variant og en forbindelse fra tabel 1 eller fra tabel 2.
11.
c-MAF-inhiberende middel til anvendelse til behandling og/eller forebyggelse af knoglemetastase ud fra brystcancer. 12. c-MAF-inhiberende middel til anvendelse til behandling og/eller forebyggelse af knoglemetastase ud fra brystcancer ifølge krav 11, hvor brystcanceren er ER+ eller ER-. 13. c-MAF-inhiberende middel til anvendelse til behandling og/eller forebyggelse af knoglemetastase ud fra brystcancer ifølge krav 10 eller 11, hvor det c-MAF-inhiberende middel er valgt fra gruppen bestående af et c-MAF-specifikt siRNA, et c-MAF-specifikt antisense-oligonukleotid, et c-MAF-specifikt ribozym, et c-MAF-inhiberende antistof, en dominerende negativ c-MAF-variant og en forbindelse fra tabel 1 eller fra tabel 2.
DK11791605.6T 2010-10-06 2011-10-05 Fremgangsmåde til diagnose, prognose og behandling af brystcancermetastase DK2626431T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201031478A ES2379918B1 (es) 2010-10-06 2010-10-06 Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama.
ES201131073 2011-06-27
PCT/ES2011/070693 WO2012045905A2 (es) 2010-10-06 2011-10-05 Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama

Publications (1)

Publication Number Publication Date
DK2626431T3 true DK2626431T3 (da) 2015-12-21

Family

ID=45099129

Family Applications (2)

Application Number Title Priority Date Filing Date
DK11791605.6T DK2626431T3 (da) 2010-10-06 2011-10-05 Fremgangsmåde til diagnose, prognose og behandling af brystcancermetastase
DK15180897.9T DK3091085T3 (da) 2010-10-06 2011-10-05 Fremgangsmåde til at designe en terapi mod brystcancermetastase

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK15180897.9T DK3091085T3 (da) 2010-10-06 2011-10-05 Fremgangsmåde til at designe en terapi mod brystcancermetastase

Country Status (14)

Country Link
US (3) US10047398B2 (da)
EP (3) EP3517630B1 (da)
JP (5) JP6159254B2 (da)
KR (2) KR102240323B1 (da)
CN (2) CN108192972B (da)
AR (1) AR083357A1 (da)
AU (4) AU2011311452B2 (da)
BR (1) BR112013008505B1 (da)
CA (1) CA2813674C (da)
DK (2) DK2626431T3 (da)
ES (3) ES2911505T3 (da)
HK (1) HK1187377A1 (da)
MX (1) MX344315B (da)
WO (1) WO2012045905A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3517630B1 (en) 2010-10-06 2022-01-19 Institució Catalana de Recerca i Estudis Avançats Method for the diagnosis, prognosis and treatment of breast cancer metastasis
EP2650682A1 (en) * 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
EP3467124A1 (en) * 2012-06-06 2019-04-10 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
EP3553186B1 (en) 2012-10-12 2021-11-17 Inbiomotion, S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US20160032400A1 (en) * 2013-03-15 2016-02-04 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
KR20150122786A (ko) * 2013-03-15 2015-11-02 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) 암 전이의 진단, 예후 및 치료를 위한 방법
US20160032399A1 (en) * 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
MX362041B (es) * 2013-10-09 2019-01-07 Fundacio Inst De Recerca Biomedica Irb Barcelona Método para el pronóstico y tratamiento de cáncer metastásico de los huesos originado de cáncer de mama.
EP2933639A1 (en) * 2014-04-16 2015-10-21 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts S100p and Hyaluronic acid as biomarkers for metastatic breast cancer
CN104398506A (zh) * 2014-12-09 2015-03-11 厦门大学 雷奈酸锶在制备预防和治疗腺癌药物中的新用途
CA2967224C (en) 2014-12-11 2023-08-22 Inbiomotion S.L. Binding members for human c-maf
AU2017271385B2 (en) * 2016-05-25 2023-10-05 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-MAF status
KR101896558B1 (ko) 2016-11-21 2018-09-07 주식회사 젠큐릭스 유방암 환자의 예후 예측 방법
CN107699619B (zh) * 2017-11-17 2019-02-22 柳超 lncRNA组合物及制备诊断预示Luminal B型乳腺癌骨转移基因诊断试剂盒的用途
WO2019102380A1 (en) 2017-11-22 2019-05-31 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf
JP2023079997A (ja) 2021-11-29 2023-06-08 東洋インキＳｃホールディングス株式会社 活性エネルギー線硬化型インクジェットインキ及び印刷物
CN114574577A (zh) * 2022-01-04 2022-06-03 中山大学孙逸仙纪念医院 Mettl16基因及其用途

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE89314T1 (de) 1985-02-13 1993-05-15 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
DE4013632A1 (de) * 1990-04-27 1991-10-31 Max Planck Gesellschaft Liposomen mit positiver ueberschussladung
EP0910652B1 (en) 1996-04-05 2014-10-08 The Salk Institute For Biological Studies Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto
DE122010000048I1 (de) 1996-12-23 2011-05-05 Immunex Corp Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6274338B1 (en) 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
AU774827B2 (en) 1999-03-15 2004-07-08 Axys Pharmaceuticals, Inc. N-cyanomethyl amides as protease inhibitors
US6287813B1 (en) 1999-04-23 2001-09-11 Cistronics Cell Technology Gmbh Antibiotic-based gene regulation system
US6525036B2 (en) 2000-01-06 2003-02-25 Merck & Co., Inc. Compounds and compositions as protease inhibitors
US6750015B2 (en) 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
NZ547695A (en) 2001-06-26 2008-09-26 Amgen Fremont Inc Antibodies to OPGL
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
AR036375A1 (es) 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
KR100485271B1 (ko) 2002-01-16 2005-04-27 메타볼랩(주) 전사인자 ｃ－ｍａｆ의 전사 활성 억제제로서의 니발레놀및 그를 포함하는 약제학적 조성물
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
DE10235624A1 (de) 2002-08-02 2004-02-19 Aventis Pharma Deutschland Gmbh Endiandric acid H und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben
US20050181375A1 (en) * 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
WO2005026322A2 (en) 2003-09-11 2005-03-24 Clontech Laboratories, Inc. siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME
TW200512298A (en) 2003-09-24 2005-04-01 Oncotherapy Science Inc Method of diagnosing breast cancer
AU2003286499A1 (en) 2003-10-17 2004-06-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Interference with c-maf function in multiple myeloma
US20090048117A1 (en) 2003-12-18 2009-02-19 President And Fellows Of Harvard College Modulation of immune system function by modulation of polypeptide arginine methyltransferases
TW200526224A (en) 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
EP1730308A4 (en) 2004-03-05 2008-10-08 Rosetta Inpharmatics Llc CLASSIFICATION OF PATIENTS OF BREAST CANCER USING A COMBINATION OF CLINICAL CRITERIA AND GENETIC INFORMATIVE SETS
WO2006012221A2 (en) 2004-06-25 2006-02-02 The Regents Of The University Of California Target cell-specific short interfering rna and methods of use thereof
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
US9134237B2 (en) 2005-09-20 2015-09-15 Janssen Diagnotics, LLC High sensitivity multiparameter method for rare event analysis in a biological sample
WO2007053245A2 (en) 2005-09-20 2007-05-10 Immunivest Corporation Methods and composition to generate unique sequence dna probes, iabeling of dna probes and the use of these probes
EP1931994A2 (en) 2005-09-26 2008-06-18 Novartis AG Molecular markers associated with bone metastasis
CA2632451C (en) 2005-12-06 2015-11-03 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2008098351A1 (en) 2007-02-14 2008-08-21 University Health Network Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
EP1961825A1 (en) * 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting the occurrence of metastasis in breast cancer patients
CA2687903C (en) 2007-05-24 2016-09-13 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2008145125A1 (en) 2007-05-31 2008-12-04 Dako Denmark A/S Methods for utilizing esr copy number changes in breast cancer treatments and prognoses
NZ562237A (en) * 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
AU2008314459A1 (en) 2007-10-18 2009-04-23 University Health Network Clioquinol for the treatment of hematological malignancies
US20110130296A1 (en) 2008-03-14 2011-06-02 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
US20110144155A1 (en) 2008-06-06 2011-06-16 Schimmer Aaron D 8-hydroxyquinoline derivatives for the treatment of hematological malignancies
ES2338843B1 (es) 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Huella genomica de cancer de mama.
US8642270B2 (en) 2009-02-09 2014-02-04 Vm Institute Of Research Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer
US20120121586A1 (en) 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
WO2011017687A1 (en) 2009-08-06 2011-02-10 Ray Partha S Diagnosis of primary and metastatic basal-like breast cancer and other cancer types
EP3517630B1 (en) 2010-10-06 2022-01-19 Institució Catalana de Recerca i Estudis Avançats Method for the diagnosis, prognosis and treatment of breast cancer metastasis
WO2012106718A2 (en) 2011-02-04 2012-08-09 Bioarray Therapeutics, Inc. Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
CA2830240A1 (en) 2011-03-15 2012-09-20 The University Of North Carolina At Chapell Hill Methods of treating breast cancer with anthracycline therapy
CA2856295A1 (en) 2011-11-18 2013-05-23 Vanderbilt University Markers of triple-negative breast cancer and uses thereof
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
EP3467124A1 (en) 2012-06-06 2019-04-10 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
EP3553186B1 (en) 2012-10-12 2021-11-17 Inbiomotion, S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US20160032400A1 (en) 2013-03-15 2016-02-04 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
KR20150122786A (ko) 2013-03-15 2015-11-02 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) 암 전이의 진단, 예후 및 치료를 위한 방법
US20160032399A1 (en) 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
MX362041B (es) 2013-10-09 2019-01-07 Fundacio Inst De Recerca Biomedica Irb Barcelona Método para el pronóstico y tratamiento de cáncer metastásico de los huesos originado de cáncer de mama.
CA2967224C (en) 2014-12-11 2023-08-22 Inbiomotion S.L. Binding members for human c-maf
AU2017271385B2 (en) 2016-05-25 2023-10-05 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-MAF status
WO2019102380A1 (en) 2017-11-22 2019-05-31 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf

Also Published As

Publication number Publication date
AU2016266009A1 (en) 2016-12-15
ES2562274T3 (es) 2016-03-03
JP2013541339A (ja) 2013-11-14
JP2017104115A (ja) 2017-06-15
CN103339265A (zh) 2013-10-02
US20190169693A1 (en) 2019-06-06
MX2013003880A (es) 2013-12-02
EP3517630B1 (en) 2022-01-19
ES2721639T3 (es) 2019-08-02
WO2012045905A2 (es) 2012-04-12
HK1187377A1 (zh) 2014-04-04
KR102240323B1 (ko) 2021-04-14
JP6571698B2 (ja) 2019-09-04
AU2011311452B2 (en) 2016-09-01
EP3091085B1 (en) 2019-02-27
ES2911505T3 (es) 2022-05-19
US20220049316A1 (en) 2022-02-17
KR20190009835A (ko) 2019-01-29
CN108192972B (zh) 2022-09-09
US11072831B2 (en) 2021-07-27
CN103339265B (zh) 2018-03-30
BR112013008505A2 (pt) 2016-07-05
AR083357A1 (es) 2013-02-21
KR20140071946A (ko) 2014-06-12
AU2019201493A1 (en) 2019-03-28
KR101944555B1 (ko) 2019-02-01
CA2813674C (en) 2020-11-24
JP2019195340A (ja) 2019-11-14
DK3091085T3 (da) 2019-05-06
EP2626431B1 (en) 2015-09-16
AU2016266009B2 (en) 2018-12-06
WO2012045905A3 (es) 2012-06-21
US10047398B2 (en) 2018-08-14
EP3091085A1 (en) 2016-11-09
AU2019201493B2 (en) 2021-03-11
BR112013008505B1 (pt) 2023-01-24
AU2011311452A1 (en) 2013-05-09
JP6946385B2 (ja) 2021-10-06
JP2021192636A (ja) 2021-12-23
JP6159254B2 (ja) 2017-07-12
MX344315B (es) 2016-12-13
EP2626431A2 (en) 2013-08-14
US20140057796A1 (en) 2014-02-27
EP3517630A1 (en) 2019-07-31
AU2021203599A1 (en) 2021-07-01
CN108192972A (zh) 2018-06-22
JP2018099132A (ja) 2018-06-28
CA2813674A1 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
DK2626431T3 (da) Fremgangsmåde til diagnose, prognose og behandling af brystcancermetastase
KR102252332B1 (ko) 암 전이의 예후 및 치료 방법
DK2859120T3 (da) Fremgangsmåde til diagnose af og prognose for lungecancermetastase
DK3055429T3 (da) Fremgangsmåde til prognose og behandling af metastaserende cancer i knoglerne, som hidrører fra brystcancer
AU2016213773B2 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-MAF
KR20150122731A (ko) 암 전이의 예후 및 치료 방법